Oregon is currently home to 1214 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Conversations With Caregivers About Health and Appearance
NCT06843200
Recruiting
This clinical trial is evaluating the effects of a 2-hour, small group discussion with parents and caregivers of adolescents in Oregon. We will evaluate whether parents'/caregivers' experience reductions in their disordered eating symptoms, mood symptoms, and parent-child relationship quality, relative to parent/caregiver participants in the wait list control. We will also evaluate whether the children of these parents/caregivers experience improvements in their disordered eating and mood sympto... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/18/2025
Locations: University of Oregon, Eugene, Oregon
Conditions: Disordered Eating Behaviors, Depression, Feeding Behaviors, Parent-Child Relations
Register for Updates
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
NCT05878860
Recruiting
This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).
Gender:
MALE
Ages:
6 years and above
Trial Updated:
02/18/2025
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: X-linked Retinoschisis
Register for Updates
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Radiation Retinopathy, Visual Impairment
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
NCT05977907
Recruiting
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Providence Cancer Institute, Portland, Oregon
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Home Sleep Therapy for Older Adults With MCI
NCT05771844
Recruiting
The goal of this clinical trial is to learn about the ability of non-invasive brain stimulation during sleep to enhance people's deep sleep and its potential benefit on memory in people with mild cognitive impairment via home use sleep therapy device (SleepWISP) as well as learn about biomarkers associated with Alzheimer disease (AD). The clinical trial aims to answer the following main questions: 1. Whether the non-invasive transcranial electrical stimulation (TES) delivered by SleepWISP could... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
02/14/2025
Locations: Brain Electrophysiology Laboratory Company, Eugene, Oregon
Conditions: Mild Cognitive Impairment, Sleep, Transcranial Electrical Stimulation, Machine Learning, Memory
Register for Updates
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593
Recruiting
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
02/12/2025
Locations: Belite Study Site, Portland, Oregon
Conditions: Geographic Atrophy
Register for Updates
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430
Recruiting
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Solid Tumor, Adult, Refractory Cancer, Cutaneous Melanoma, Non-small Cell Lung Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum
Register for Updates
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT04005690
Recruiting
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
NCT06196203
Recruiting
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Oncology Associates of Oregon, Eugene, Oregon
Conditions: Higher-risk Myelodysplastic Syndromes
Register for Updates
Reducing Drug Use in Justice-Involved Emerging Adults
NCT05834881
Recruiting
The overarching purpose of this pilot study is to investigate an increasingly common, but under-researched, practice of employing paraprofessional coaches to improve emerging adults' access to and engagement in evidence-based substance use practices, focusing on the paraprofessional coaches' outcomes and the role of lived experience.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
02/07/2025
Locations: Chestnut Health Systems, Eugene, Oregon
Conditions: Substance-Related Disorders
Register for Updates